Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial for the Assessment of Lipid Trends and Safety of RVX000222 in Statin Treated Subjects With Low Baseline HDL-C Concentrations

NCT01423188 is registered in ClinicalTrials.gov with Resverlogix Corp as lead sponsor.

NCT NCT01423188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01423188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial for the Assessment of Lipid Trends and Safety of RVX000222 in Statin Treated Subjects With Low Baseline HDL-C Concentrations
Lead sponsor
Resverlogix Corp
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2011
Completion date
August 31, 2012
Enrollment
176 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, dyslipidemia